These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 8035933

  • 1. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease.
    Sawle GV, Burn DJ, Morrish PK, Lammertsma AA, Snow BJ, Luthra S, Osman S, Brooks DJ.
    Neurology; 1994 Jul; 44(7):1292-7. PubMed ID: 8035933
    [Abstract] [Full Text] [Related]

  • 2. Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease.
    Ruottinen HM, Rinne JO, Ruotsalainen UH, Bergman JR, Oikonen VJ, Haaparanta MT, Solin OH, Laihinen AO, Rinne UK.
    J Neural Transm Park Dis Dement Sect; 1995 Jul; 10(2-3):91-106. PubMed ID: 9620057
    [Abstract] [Full Text] [Related]

  • 3. Effect of catechol-O-methyl transferase inhibition on peripheral and central metabolism of 6-[18F]fluoro-L-dopa.
    Pauwels T, Dethy S, Goldman S, Monclus M, Luxen A.
    Eur J Pharmacol; 1994 May 12; 257(1-2):53-8. PubMed ID: 8082707
    [Abstract] [Full Text] [Related]

  • 4. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
    Ruottinen HM, Rinne JO, Oikonen VJ, Bergman JR, Haaparanta MT, Solin OH, Ruotsalainen UH, Rinne UK.
    Synapse; 1997 Dec 12; 27(4):336-46. PubMed ID: 9372556
    [Abstract] [Full Text] [Related]

  • 5. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis.
    Ishikawa T, Dhawan V, Chaly T, Robeson W, Belakhlef A, Mandel F, Dahl R, Margouleff C, Eidelberg D.
    J Cereb Blood Flow Metab; 1996 Sep 12; 16(5):854-63. PubMed ID: 8784230
    [Abstract] [Full Text] [Related]

  • 6. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys.
    Lyras L, Zeng BY, McKenzie G, Pearce RK, Halliwell B, Jenner P.
    J Neural Transm (Vienna); 2002 Sep 12; 109(1):53-67. PubMed ID: 11793162
    [Abstract] [Full Text] [Related]

  • 7. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.
    Guttman M, Léger G, Reches A, Evans A, Kuwabara H, Cedarbaum JM, Gjedde A.
    Mov Disord; 1993 Jul 12; 8(3):298-304. PubMed ID: 8341294
    [Abstract] [Full Text] [Related]

  • 8. [18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462).
    Laihinen A, Rinne JO, Rinne UK, Haaparanta M, Ruotsalainen U, Bergman J, Solin O.
    Neurology; 1992 Jan 12; 42(1):199-203. PubMed ID: 1734304
    [Abstract] [Full Text] [Related]

  • 9. Effect of catechol-O-methyltransferase inhibition on brain uptake of [18F]fluorodopa: implications for compartmental modelling and clinical usefulness.
    Léger G, Gjedde A, Kuwabara H, Guttman M, Cumming P.
    Synapse; 1998 Dec 12; 30(4):351-61. PubMed ID: 9826227
    [Abstract] [Full Text] [Related]

  • 10. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H.
    Mov Disord; 1997 Jul 12; 12(4):497-505. PubMed ID: 9251066
    [Abstract] [Full Text] [Related]

  • 11. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
    Müller T, Schlegel E, Zingler S, Thiede HM.
    Cells; 2022 Apr 30; 11(9):. PubMed ID: 35563817
    [Abstract] [Full Text] [Related]

  • 12. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.
    Paija O, Laine K, Kultalahti ER, Leinonen M, Huupponen R, Gordin A, Reinikainen K.
    Clin Neuropharmacol; 2005 Apr 30; 28(3):115-9. PubMed ID: 15965309
    [Abstract] [Full Text] [Related]

  • 13. Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets.
    Smith LA, Gordin A, Jenner P, Marsden CD.
    Mov Disord; 1997 Nov 30; 12(6):935-45. PubMed ID: 9399218
    [Abstract] [Full Text] [Related]

  • 14. The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J, Sovijärvi A, Kaakkola S, Gordin A, Teräväinen H.
    Clin Neuropharmacol; 2001 Nov 30; 24(1):50-7. PubMed ID: 11290882
    [Abstract] [Full Text] [Related]

  • 15. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.
    Heikkinen H, Varhe A, Laine T, Puttonen J, Kela M, Kaakkola S, Reinikainen K.
    Br J Clin Pharmacol; 2002 Oct 30; 54(4):363-71. PubMed ID: 12392583
    [Abstract] [Full Text] [Related]

  • 16. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
    Heikkinen H, Nutt JG, LeWitt PA, Koller WC, Gordin A.
    Clin Neuropharmacol; 2001 Oct 30; 24(3):150-7. PubMed ID: 11391126
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M, Leinonen M, Poewe W.
    J Neural Transm (Vienna); 2015 Dec 30; 122(12):1709-14. PubMed ID: 26347184
    [Abstract] [Full Text] [Related]

  • 18. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW.
    Ann Neurol; 2010 Jul 30; 68(1):18-27. PubMed ID: 20582993
    [Abstract] [Full Text] [Related]

  • 19. Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats.
    Törnwall M, Kaakkola S, Tuomainen P, Kask A, Männistö PT.
    Br J Pharmacol; 1994 May 30; 112(1):13-8. PubMed ID: 7518301
    [Abstract] [Full Text] [Related]

  • 20. Altered metabolism of [18F]-6-fluorodopa in the hooded rat following inhibition of catechol-O-methyltransferase with U-0521.
    Cumming P, Boyes BE, Martin WR, Adam M, Ruth TJ, McGeer EG.
    Biochem Pharmacol; 1987 Aug 01; 36(15):2527-31. PubMed ID: 3111485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.